Ads
related to: merck- Cell Therapy Production
Cell Therapy Manufacturing Services
From Clinical To Commercial
- AAV Reference Standards
Essential AAV Reference Standards
Full & Empty Capsids of 6 Serotypes
- GMP Retrovirus Services
cGMP-compliant & fully scalable
Viral vector manufacturing
- GMP QC Services
Viral Vector & Plasmid Assays
Quality, Sterility & Potency
- Cell Therapy Production
Search results
Merck is spending $3 billion on an eye drug developer as it braces to lose a key cancer patent
Quartz· 2 days agoPharma giant Merck said on Wednesday that it is acquiring the privately-held eye drug developer...
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
Zacks via Yahoo Finance· 2 days agoMerck KGaA (MKGAF) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co...
Benzinga· 2 days agoMerck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum...
Merck to Buy Eye Drug Company Eyebiotech for Up to $3 Billion. It’s Doubling Down on Deals.
Barrons.com· 2 days agoThe pharmaceutical company agrees to buy eye drug company Eyebiotech for up to $3 billion as it...
Merck to buy eye drug developer for $1.3B
BioPharma Dive via Yahoo Finance· 2 days agoAn acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
Zacks· 2 days agoFree Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...
Summit Therapeutics cancer therapy succeeds in late-stage China study
Reuters via AOL· 12 hours agoThe company said its therapy showed statistically significant improvement compared to Merck's Keytruda in a head-to-head setting. The study sponsored by Akeso showed the therapy ...
Merck to buy eye-focused drug developer EyeBio for as much as $3 bln
Reuters· 2 days agoThe deal is the latest in a string of recent acquisitions by Merck to reduce its reliance on...
Merck to buy EyeBio in a deal that could valued at up to $3 billion
Market Watch· 2 days agoannounced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused...
Merck to acquire eye drug company EyeBio for up to $3 billion
WSAU Wausau· 2 days ago(Reuters) - Merck said on Wednesday it would acquire eye disease drug developer EyeBio for up to $3...